+44 (0)1865 595230
0 Items

Giardia

Giardia lamblia is an anaerobic, flagellated eukaryotic protozoan and member of the Hexamitidae family of protozoa. Giardia lamblia infects and colonises the small intestine of humans and mammals, causing a globally-common diarrheal disease, known as giardiasis.

The Native Antigen Company offers Giardia monoclonal antibodies for use in immunoassay development.

Giardia Background

Giardia lamblia exists in two forms, as a dormant cyst that infects the small intestine and as a trophozoite – a vegetative form that excysts from the cyst. Trophozoites replicate within the intestine causing the symptoms associated with giardiasis. Both cysts and trophozoites are present in contaminated faeces, but trophozoites do not survive for long periods in the environment. G. lamblia cysts are found in soil and water, and on surfaces contaminated by faeces from an infected individual. Giardiasis infection in humans occurs by transmission of dormant G. lamblia cysts via the faecal oral route or through ingestion of contaminated food and water (CDC).

Giardia Antibodies

Our Giardia-specific antibodies are specific to the trophozoite protein of Giardia lamblia. These antibodies do not cross react with Campylobacter spp., Clostridium difficile, Cryptosporidium parvum, Entamoeba histolytica, Escherichia coli, Helicobacter pylori, Listeria monocytogenes, Salmonella spp., Shigella spp. or Staphylococcus aureus.

We also have two monoclonal antibodies available, which may be used as pairs in immunoassay development.

Questions?

Check out our FAQ section for answers to the most frequently asked questions about our website and company.

Challenges to Effective Yellow Fever Diagnostics

Yellow fever is a haemorrhagic viral disease, transmitted by infected mosquitos in Africa and South America. While an effective vaccine is available, inadequate vaccination of endemic areas has made diagnostics a necessity to controlling ongoing outbreaks. However,...

Five Methods You Can Use to Overcome Zika-Dengue Cross-Reactivity

Cross-reactivity between the Zika and Dengue viruses in serological assays is one of the biggest challenges faced by the epidemiologists, academics and pharmaceutical companies trying to control the Zika epidemic, as it brings the quality and reliability of diagnostic...

Why Zika virus’s cross-reactivity with Dengue might be hampering your research

Given the impact of Zika, it’s no surprise that a global contingent of epidemiologists, academic researchers, and pharmaceutical companies are striving to develop effective disease control measures and treatments. One challenge currently hindering the...

How The Native Antigen Company responds to the WHO list of priority infectious diseases

In 2015, a broad group of public health and science experts gathered in Geneva to discuss emerging infectious diseases that are likely to cause future severe epidemics and public health emergencies. Organised by the World Health Organization (WHO), their aim was to...

Native Antigen release a panel of serotype specific monoclonal antibodies

  There are four distinct serotypes of Dengue Virus circulating around the world, causing Dengue fever infection which is the most important worldwide arboviral disease. There are nearly 400 million cases of Dengue annually, and around 25% present with so called...

Get in Touch

We sometimes send exclusive information and offers to our customers - please let us know if you are happy to receive these

3 + 15 =

Live Customer Feedback